No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission

Jean Yves Cahn, Myriam Labopin, Jorge Sierra, Didier Blaise, Josy Reiffers, Augustin Ferrant, Lothar Bergmann, Giuseppe Visani, Jan Cornelissen, Theo De Witte, Alberto Bosi, Francesco Frassoni, Norbert Claude Gorin

Research output: Contribution to journalArticle

Abstract

High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.

Original languageEnglish
Pages (from-to)308-314
Number of pages7
JournalBritish Journal of Haematology
Volume110
Issue number2
DOIs
Publication statusPublished - 2000

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Stem Cell Transplantation
Anthracyclines
Homologous Transplantation
Bone Marrow Transplantation
Disease-Free Survival
Registries
Leukemia
Therapeutics
Recurrence
Drug Therapy
Incidence

Keywords

  • Acute myeloblastic leukaemia
  • Bone marrow transplantation
  • Cytarabine

ASJC Scopus subject areas

  • Hematology

Cite this

No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. / Cahn, Jean Yves; Labopin, Myriam; Sierra, Jorge; Blaise, Didier; Reiffers, Josy; Ferrant, Augustin; Bergmann, Lothar; Visani, Giuseppe; Cornelissen, Jan; De Witte, Theo; Bosi, Alberto; Frassoni, Francesco; Gorin, Norbert Claude.

In: British Journal of Haematology, Vol. 110, No. 2, 2000, p. 308-314.

Research output: Contribution to journalArticle

Cahn, JY, Labopin, M, Sierra, J, Blaise, D, Reiffers, J, Ferrant, A, Bergmann, L, Visani, G, Cornelissen, J, De Witte, T, Bosi, A, Frassoni, F & Gorin, NC 2000, 'No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission', British Journal of Haematology, vol. 110, no. 2, pp. 308-314. https://doi.org/10.1046/j.1365-2141.2000.02178.x
Cahn, Jean Yves ; Labopin, Myriam ; Sierra, Jorge ; Blaise, Didier ; Reiffers, Josy ; Ferrant, Augustin ; Bergmann, Lothar ; Visani, Giuseppe ; Cornelissen, Jan ; De Witte, Theo ; Bosi, Alberto ; Frassoni, Francesco ; Gorin, Norbert Claude. / No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. In: British Journal of Haematology. 2000 ; Vol. 110, No. 2. pp. 308-314.
@article{b7db1ae7d7b34c7f934c03b2c1fe40c9,
title = "No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission",
abstract = "High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.",
keywords = "Acute myeloblastic leukaemia, Bone marrow transplantation, Cytarabine",
author = "Cahn, {Jean Yves} and Myriam Labopin and Jorge Sierra and Didier Blaise and Josy Reiffers and Augustin Ferrant and Lothar Bergmann and Giuseppe Visani and Jan Cornelissen and {De Witte}, Theo and Alberto Bosi and Francesco Frassoni and Gorin, {Norbert Claude}",
year = "2000",
doi = "10.1046/j.1365-2141.2000.02178.x",
language = "English",
volume = "110",
pages = "308--314",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission

AU - Cahn, Jean Yves

AU - Labopin, Myriam

AU - Sierra, Jorge

AU - Blaise, Didier

AU - Reiffers, Josy

AU - Ferrant, Augustin

AU - Bergmann, Lothar

AU - Visani, Giuseppe

AU - Cornelissen, Jan

AU - De Witte, Theo

AU - Bosi, Alberto

AU - Frassoni, Francesco

AU - Gorin, Norbert Claude

PY - 2000

Y1 - 2000

N2 - High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.

AB - High-dose cytarabine is currently used in combination with anthracycline in the treatment of acute myeloblastic leukaemia (AML). Moreover, high-dose cytarabine has been reported to produce long-term disease-free survival in a proportion of patients, especially in certain subtypes of AML. However, it remains unknown whether the outcome of patients undergoing allogeneic or autologous stem cell transplantation is influenced by previous treatment with high-dose cytarabine. To this end, 1672 patients with AML in first remission who were reported to the Acute Leukaemia Working Party registry of the European Group for Blood and Marrow Transplantation (EBMT) and who were transplanted between 1980 and 1995 were analysed according to the dose intensity of cytarabine given at induction and/or consolidation. Autologous stem cell transplantation (ABMT) was performed in 846 patients and allogeneic bone marrow transplantation (BMT) in 826 patients. This study shows that the dose of cytarabine (Ara-C) given at induction and/or consolidation did not influence the relapse incidence in patients subsequently allografted or autografted. In addition, it did not give any advantage in terms of overall outcome. Therefore, high-dose (HD) Ara-C may not be needed for patients who have a planned stem cell transplantation (SCT) as post-remission therapy. Nevertheless, HD Ara-C may be utilized in certain subtypes of AML that are believed to be curable by chemotherapy alone.

KW - Acute myeloblastic leukaemia

KW - Bone marrow transplantation

KW - Cytarabine

UR - http://www.scopus.com/inward/record.url?scp=0033840785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033840785&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.02178.x

DO - 10.1046/j.1365-2141.2000.02178.x

M3 - Article

C2 - 10971386

AN - SCOPUS:0033840785

VL - 110

SP - 308

EP - 314

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -